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Context of project and the student’s role 
This project was not the project I originally arranged for my Workplace Portfolio.  After 
that project with the Cancer Council fell through due to issues with granting me security to 
their premises after-hours, I found this project through one of the surgeons currently 
supervising my surgical training, Associate Professor Andrew Spillane.  He is an academic 
melanoma surgeon at the Sydney Melanoma Unit and Royal North Shore Hospital. 
The hypothesis of the project arose from the known common practice of some 
surgeons of retrieving only the lymph nodes which were detectable at operation rather 
than attempting to retrieve all the nodes detected at lymphoscintigraphy.  Hand-held 
gamma probe, blue dye and surgical intuition were used to find these nodes.   It was 
hypothesized that this surgical (mal)practice may lead to missed detection of nodal 
involvement and therefore potentially poorer patient outcomes. 
At the time of my involvement, the project had already commenced with data 
collection by Dr Nicholas Lee, a junior surgical trainee.  My role was therefore: 
• to advise Dr Nicholas Lee regarding important missing data from his dataset 
and how to obtain them most efficiently; 
• Data cleaning and manipulation of data from a datasheet with significant flaws 
in its original design; 
• discussing with Dr Nicholas Lee and A/Prof Spillane regarding the appropriate 
analysis and implementing it; 
• Assisting their interpretation of the results. 
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Most of my time involved data manipulation to extract information efficiently from the 
relatively large dataset.  All data manipulation and statistical analysis were performed by 
me.   
Due to problems with initial data collection necessitating re-collection of much of the 
data from a dataset of more than 3000 patients, there were significant delays in 
commencing data manipulation and analysis.  This significantly hampered my ability to 
consult my statistics supervisor regarding the details of analysis.  Despite this, the project 
was eventually successfully completed albeit slightly late compared to the original timeline. 
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Preface 
This project has been very instructive for my development as a biostatistician.  It has 
allowed me to appreciate that in addition to considering the statistical aspects, there are 
many other aspects to the biostatistician’s work.  My reflections on the whole learning 
experience is documented below. 
I played a dual role in this project.  Being from a clinical background (surgical trainee in 
general surgery) I had a unique insight into the aims of the current project and how it may 
affect future surgical practice.  I also had an understanding of what important variables 
affect survival of melanoma patients and what results are clinically important.  However, 
this advantage was also initially a disadvantage as it made me feel that I should try to 
handle all aspects of the project myself.  This especially occurred in the early part of this 
project.  It also meant that I wrongly assumed that other clinical staff involved in this 
project had a good grasp of statistical and data management issues.   
Communication skills 
This led to a major problem when I received the Excel datasheet for analysis.  To my 
surprise the survival and recurrence data collected consisted of a yes/no column of survival 
and recurrence at 5 years (ie, a binary indicator variable which indicated if death or 
recurrence occurred within 5 years).  At that point I realized the importance of the role of 
the biostatistician to educate and guide the other team members regarding data and 
statistical aspects of the project.  So after discussion with Dr Lee the main investigator, data 
collection was recommenced.   
From that point on, I started to take a much more active role in communicating with 
other members of the research team.  This included: 
viii 
 
• frequent discussion with Dr Lee, who was involved in data collection regarding 
his progress and how the data can be rapidly retrieved as a large quantity of 
data required recollection despite a rapidly approaching deadline; 
• discussion with the database manager regarding what kind of data is available 
and how it could be extracted from the database in a form that can be easily 
manipulated; 
• my scientific supervisor regarding the exact question he wanted this study to 
answer and how we may go about analysing the data to answer this. 
As a result, my communication skills were enhanced greatly during the course of this 
project. 
There was a constant great pressure to complete this project as quickly as possible as 
the unsuccessful commencement of the original project with the Cancer Council meant that 
this current project only commenced mid-semester.  Adding to this narrow timeline was 
the failure of the initial data collection, and the need to recollect data for more than 3100 
patients. 
Work patterns/planning 
As Dr Lee, A/Prof Spillane and I worked at the same hospital, we were able to arrange 
frequent communication to ensure no delays in the project.  Because of this frequent 
communication, we were able to deal with any potential delaying issues rapidly.  For 
instance, when it was apparent that follow-up data had to be recollected for all 3113 
patients, A/Prof Spillane was able to rapidly arrange a meeting between the database 
manager, Dr Phil Brown and myself to discuss how the necessary data could be extracted 
without having to access all 3113 records manually. 
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One of the major differences between real life datasets and datasets in books and 
courses on survival modelling was the presence of missing data.  This project greatly 
increased my understanding in this area, especially in realizing the differences between 
data MCAR (missing completely at random) and MAR (missing at random).  Through 
additional reading of texts and journal articles, I also learnt of different strategies of dealing 
with missing data (eg, exclusion, indicator method, single imputation, multiple imputation) 
and the advantages and disadvantages of each of these.  In addition, the experience of 
multivariate modelling of a disease process with which I am familiar gave me an 
appreciation of the importance of clinical input in this process rather than relying on a 
purely mechanical stepwise approach. 
Statistical issues, principles and computing 
This project has also furthered my familiarity with using Stata in applying descriptive 
analysis (Kaplan-Meier curves), univariate analysis (log rank test), multivariate analysis (Cox 
proportional hazards models) and model diagnostics (Cox-Snell residuals, Martingale 
residuals, etc) for survival analysis. 
Finally, data manipulation of poorly coded datasets has greatly improved my Excel skills 
especially in the use of conditional (IF statements) formulae, logical (AND/OR etc) formulae, 
data lookup formulae (VLOOKUP), and text search and manipulation formulae (MID, FIND 
commands). 
Teaching has become a major part of my role in the team.  I was involved in educating 
the clinical team members and the database manager about some basic survival analysis 
principles and the data requirements of survival analysis.  Also, I noted problems with 
Teamwork 
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coding the data on the datasheet and was able to educate the clinical team member 
involved in data collection regarding how best to organize and code the data.  For instance, 
when I noticed that some columns in the Excel datasheet consisted of 2 pieces of 
information, such as “SSM 1.5mm”, I was able to educate the team member that it is best 
to have a column with a code for the tumour type (SSM) and a separate numerical column 
for depth in mm (1.5). 
Ethical considerations are also an important part of statistical analysis.  This is especially 
important in experimental studies which involve treatments that are considered non-
standard.   It is less of an issue in retrospective database analyses like the current study. 
Ethical considerations 
  For the present study, potential ethical issues were considered.  However, according 
to NHMRC guidelines, as this satisfies the criteria as an audit of an existing database,  
independent Human Research Ethics Committee (HREC) approval was not required.1 
Confidentiality is an important aspect of any study.  As far as possible, data were 
identified with patient identification numbers (PIN) rather than their names.  Addresses and 
other non-essential personal information were not extracted from the database.   
Confidentiality and professional responsibility 
Security of the data depends both on the security of database access and that of the 
data extracted from the database.  Database access was strictly available for investigators 
of the Sydney Melanoma Unit (SMU) approved research projects.  It is available either on 
site at the SMU or offsite through a password encrypted Citrix platform on the internet.  
User-specific passwords were issued to the investigators of this project.  Data contained 
within the Excel files were de-identified to ensure patient confidentiality.   
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Finally, important professional responsibilities such as not accessing unnecessary 
personal information of subjects, keeping the data secure, and not professing to know or 
have the ability to do something that I do not know were also adhered to.  
Overall, I have learnt a lot from this project.  In addition to putting what I have learnt in 
the Master of Biostatistics into practice, and sharpening my statistical ability, I have learnt 
much about the non-statistical and professional aspects of being a biostatistician. 
Conclusion 
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Abbreviations list 
• AL – Acral lentiginous melanoma 
• HR – Hazards ratio 
• HREC – Human Research Ethics Committee 
• LMM – Lentigo maligna melanoma 
• LN – lymph node(s) 
• LSG – (number of) lymph nodes detected on lymphoscintigraphy 
• MAR – (data) Missing at random 
• MCAR – (data) Missing completely at random 
• MI – Multiple imputation 
• NM – nodular melanoma 
• PIN – patient identity numbers 
• SLN – (number of) sentinel lymph node(s) 
• SLNB – Sentinel lymph node biopsy 
• SMU – Sydney Melanoma Unit 
• SSM – Superficial spreading melanoma 
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Glossary of medical terms 
• Gamma camera – a device used to image a gamma radiation source.  It produces an 
image of the distribution of radionuclide (eg, technetium-99) in the area of interest 
(eg, lymph node basin); 
• Intradermal injection – an injection into the dermal layer of the skin (the layer 
between the epidermis and subcutaneous tissues); 
• Lymph node basin – the collection of lymph nodes where lymph drains into from an 
anatomical site (eg, the lymph node basin of the arm is the axilla) 
• Lymphoscintigraphy – a nuclear medicine imaging test that provides a picture of 
the lymphatic system using small amounts of radioactive material injected into the 
skin.  This radioactive material travels in the lymph vessels and the radiation 
released is captured using a gamma camera and recorded to form an image. 
• Patent blue dye – a pigment material which is carried in the lymph vessels and dyes 
them blue temporarily, allowing their identification at surgery. 
• Peritumoural injection – an injection of a substance into the vicinity of, but not into, 
the tumour. 
• SPECT (Single Photon Emission Computed Tomography) – is a special type of 
nuclear scan which produces a 3-dimensional view of the distribution of 
radionuclide in the body.  It uses a gamma camera to acquire multiple 2-
dimensional images at different angles which are then combined by a computer to 
form a 3 dimensional model. 
• Abstract 
Introduction: During sentinel lymph node biopsy (SLNB), the yield of sentinel lymph nodes 
(SLN) is not always equal to the number of nodes identified at lymphoscintigraphy.  We 
hypothesise that this (the “completeness” of SLNB) is related to patient outcome. 
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Methods: Retrospective case series of 3113 consecutive patients with cutaneous 
melanoma and SLNB at Sydney Melanoma Unit, a tertiary referral centre.  Study period: 
January 1995-April 2008.  Missing data was assumed to be missing at random and multiple 
imputation (5 imputations) was used to estimate this missing data.  Proportional hazards 
model was used for multivariate analysis.  Appropriate model diagnostics were performed.  
Stratification was used to overcome violations to the proportional hazards assumption. 
Results: Median follow-up was 47 (IQR 24 -71) months.  Median overall-survival was not 
reached.  Overall 75% survival time was 74 months.  75% disease-free survival time was 44 
months.  Univariate analysis demonstrated that lymph node yield was associated with 
improved overall and disease-free survival (P=0.011 and 0.0052 respectively).  The 
multivariate overall survival model was stratified for lymph node location and presence of 
positive lymph nodes at SLNB.  It showed that the lymph node yield did not significantly 
affect survival (P=0.21, HR=0.88 (95% CI 0.72-1.08)).  Male sex, old age, presence of 
ulceration, high mitotic count, and thicker tumours were associated with poorer overall 
survival.   The multivariate disease-free survival was stratified for age, presence of positive 
lymph nodes and ulceration.  LN yield was again not found to significantly affect disease-
free survival (P=0.17, HR=0.90 (95%CI 0.76-1.05).  Sex, lymph node location, mitotic count 
and Breslow thickness were found also to significantly affect disease-free survival.  
Conclusion: Lymph node yield at SLNB was not found to significantly affect either overall 
survival or disease-free survival. 
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Background 
Cutaneous melanoma is a malignant neoplasm of skin melanocytes.  In 2002, it was 
ranked as the 4th most common malignant neoplasm and ninth most common cancer 
causing death in Australia and New Zealand.  Over the period 1991-2003, the incidence of 
melanoma in Australia showed an upward trend.2   
The management of melanoma can be divided into the management of: 
(1) The primary tumour 
(2) The draining lymph node basin 
(3) Locoregional recurrence 
(4) Distant recurrences/metastases. 
The topic of the current study is sentinel lymph node biopsy which is one strategy in the 
management of occult lymph node disease. 
Sentinel lymph node biopsy is a technique used in cancer treatment where the first 
draining lymph node(s) from the site of the primary tumour, the sentinel node, is sampled 
to look for metastatic disease.  The rationale for this arose from the observation that there 
is a tendency for melanoma and other cancers to progress in a stepwise orderly manner 
from primary tumour site, through the local lymph drainage basin then beyond.  This 
stepwise concept of tumour spread was thought also to occur within lymph node basins, in 
that the first lymph node draining the primary tumour would have a high probability of 
being involved if lymph node metastasis has occurred.   
The very early evidence for this was presented by Morton and colleagues.3  This was 
supported by the finding that positive sentinel lymph nodes are associated with early 
locoregional and distant recurrence.4   
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Despite this, controversy still surrounds sentinel node biopsy and its potential benefits 
in melanoma patients.  While many studies have reported low false negative rates, a recent 
study has suggested that this may be much higher (between 10-20%).5  In addition, the 
third interim analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT1) 
suggested that, while there was a small melanoma-specific survival improvement at 3 years 
in the sentinel lymph node group, there was no overall survival benefit.6 
Could the inconsistencies in the literature be related to quality of surgery, specifically, 
the lymph node yield at surgery? 
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Hypothesis 
Complete excision of all lymphoscintigraphy-detected sentinel lymph 
nodes at surgery is associated with improved patient outcomes (overall 
survival and disease-free survival). 
Aims of the study 
The three aims of this study are: 
• To describe the patients undergoing sentinel lymph node biopsy at the Sydney 
Melanoma Unit (SMU), particularly, to determine the frequency of incomplete 
sentinel node biopsies (SNB); 
• To assess whether complete SNB is associated with improved disease-free 
survival; and 
• To assess whether complete SNB is associated with improved overall survival. 
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Methods 
This study is a retrospective case series of 3113 consecutive patients who had 
cutaneous melanoma and a sentinel lymph node biopsy at the Sydney Melanoma Unit 
(SMU), a tertiary referral centre for melanoma treatment.  The study period was from 
January 1995 to April 2008.  These patients were identified from the SMU melanoma 
patient database, which is a prospectively maintained database of all patients treated at 
the SMU and includes demographic, clinical, operative, pathological and follow-up data. 
Data collected from the database included demographic characteristics (sex, age), 
sentinel node data (date of sentinel lymph node dissection, area of lymph node basin, 
number of nodes detected at lymphoscintigraphy, number of nodes actually sampled, 
number of nodes positive) and primary tumour characteristics (type of growth pattern, 
Breslow thickness, presence of ulceration, mitotic count).  
Formal ethics committee approval was not obtained for this study as it is within the 
NHMRC definition of an audit.1 
Brief scientific methods 
All patients with biopsy-proven melanoma of thickness greater than 1mm should 
undergo sentinel lymph node biopsy according to the Clinical Practice Guidelines for the 
Management of Melanoma.2 
On the morning of surgery, these patients attended the local nuclear medicine 
department to undergo lymphoscintigraphy.  In this procedure, the primary tumour site 
was injected intradermally with technetium 99m-labelled colloid and the lymph drainage 
basins were imaged with a gamma camera.  Routine SPECT (Single Photon Emission 
Computed Tomography) scanning was not utilized.  The skin areas over the imaged sentinel 
nodes (“hot” areas) were marked to assist intraoperative localization. 
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In the operating theatre just before the commencement of the operation, a 2mL 
intradermal peritumoral injection of Patent Blue dye (Patent Blue V, Aspen Pharmacare) 
was performed.  A skin incision was placed over the image-detected sentinel nodes and 
these nodes are carefully dissected out, guided by blue-dyed lymphatic vessels.  The 
sentinel nodes are detected at operation visually (they should be stained blue) and by the 
use of a hand-held gamma probe.  These lymph nodes are excised.  Ex-vivo radioactive 
counts were performed with the gamma probe and any other nodes with a count more 
than 10% of that of the hottest node or which are dyed blue are considered sentinel nodes 
even if they were not preoperatively identified by lymphoscintigraphy. 
Definitions 
Lymph node yield was defined as the number of lymph nodes extracted at surgery 
divided by the number of lymph nodes detected at lymphoscintigraphy.  The number of 
lymph nodes extracted at surgery was defined as the number of lymph nodes counted on 
histopathological examination of the operative specimen. 
In this study, death was defined as all-cause death.  Locoregional recurrence was 
defined as recurrence at the site of the primary melanoma, in-transit metastases and 
regional lymph node recurrence.  Distant recurrence was defined as distant organ 
metastases or lymphatic metastases distant from the primary draining lymphatic basin. 
For the analysis of overall survival, the event of “failure” was defined as death from any 
cause.  Disease-free survival was defined as survival with no sign of recurrence.  For 
disease-free survival analysis, 3 events were considered “failures”: death from any cause, 
locoregional recurrence or distant recurrence.  Survival times of patients who did not 
experience any of the relevant failures for each analysis were censored at the time of last 
follow-up.  
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Data acquisition and management 
The database was located on-site at the Sydney Melanoma Unit, but was accessible 
remotely through the internet via a secure Citrix server.  It is managed by a database 
manager, Dr Phil Brown.  Data were acquired by searching the database for all patients who 
underwent SNB during the study period.  3127 patients were initially identified.   
Microsoft Excel 2007 and Intercooled Stata 9.1 (Statacorp TX USA) were used for data 
management and cleaning.  Intercooled Stata 9.1 was used for all data analysis.  The Stata 
routine, ice, was downloaded and used for multiple imputation of missing data.7 
The data for the study comprised 2 parts: 
• Patient demographic characteristics and details of the operation and pathology 
findings 
• Survival related data (events table) from another table in the database. 
Before these data could be analysed, the following procedure had to be followed to 
extract the appropriate data into an integrated datasheet which could be analysed using 
Stata. 
The basic demographic characteristics and the survival/recurrence data were generated 
from the database by the database manager using an SQL command to merge a list of 
patient ID numbers with the relevant tables within the database.  However, this meant that 
there were two Microsoft Excel data tables – an Excel file with 3127 patient and tumour 
details and a separate Excel file of 25991 separate “events” (ie, treatments, recurrences 
and deaths) for these 3127 patients.  Using a combination of conditional and lookup Excel 
formulae, I extracted appropriate lists of events (death, recurrence, last follow-up) and 
copied them into the main dataset. 
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Two of the original variables were “compound” variables comprised of more than one 
piece of information for each patient.  These were: 
• Number of positive lymph nodes, recorded as  
o the number of positive nodes at pathology/number of nodes retrieved, 
eg, ‘1/2’ or ‘2/3’ 
• Histological type, recorded as 
o Type and Breslow thickness – eg, ‘SSM 2.3’ for superficial spreading 
melanoma 2.3mm deep. 
These “compound variables” were divided into their separate component variables 
using conditional FIND and MID text search commands in Excel.  Using conditional 
statements, any inconsistencies were flagged by the text “error” which could be searched 
for and corrected manually.  Any missing data were completed where possible by retrieving 
the patient’s medical record to extract the relevant data. 
Details of Excel commands used in this project are given in Appendix 1. 
Data cleaning 
Data obtained from the database were checked for errors.  The following procedure 
was undertaken: 
• Duplicate records were checked for.  The unique key for each patient was the 
variable “PIN”.  This was checked to ensure no duplicates were present in the 
data. 
• Frequency tables were produced for each categorical variable to ensure only 
possible values were recorded.  For example, to ensure that sex was coded 
either 1 (males) or 0 (females); Clark levels can only be coded 1, 2, 3, 4, 5. 
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• If a logical relationship exists between variables, this was checked for 
consistency.  For example, there must be fewer positive nodes than the 
number of lymph nodes extracted at surgery (as the former is a subset of the 
latter). 
• The variable “histological type” was checked to ensure all patients indeed had 
malignant melanoma.   
• For continuous variables, values outside a reasonable or expected range were 
identified and checked with Dr Lee to confirm accuracy of the data.  For 
example, age outside the range 5-95 years old or Breslow thickness <0 or 
>15mm.  If an error was found in the database and the value could not be 
confirmed but was considered “impossible”, it was replaced by “.” (missing 
value). 
• Dates were checked to be in the correct order such that: 
o Date of birth < date of sentinel lymph node biopsy < date of recurrence 
< date of death or last follow-up. 
At the completion of data cleaning and acquisition the following variables were imported 
into Stata for analysis. 
• PIN – patient identification number (unique identifier) 
• codemf – patient sex: 1=Male; 0=Female 
• dob – Date of birth 
• datesnb – Date of sentinel lymph node biopsy 
• Age – Age in years calculated as (datesnb-dob)/365.25 
• lnarea – lymph node area (1=axilla/upper limb; 2=groin/lower limb; 
3=head/neck/axial; 4=multiple) 
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• lr – left or right side (0=left; 1=right; 2=bilateral) 
• LSG – number of lymph nodes detected by lymphoscintigraphy 
• SLN – number of lymph nodes removed at surgery 
• LNpos – number of sentinel nodes positive for metastatic cancer 
• mitosis – number of mitosis per square millimetre 
• clarklev – Clark level (1=intraepidermal with intact basement membranes; 
2=invasion to papillary dermis; 3=to junction between papillary and reticular 
dermis; 4=invasion into reticular dermis; 5=invasion into subcutaneous fat) 
• ulcer – presence of ulceration (0=absence of ulceration; 1=presence of ulceration) 
• Breslow – Breslow thickness (in millimetres) 
• type – tumour type (1=superficial spreading; 2=nodular melanoma, 3=acral 
lentiginous melanoma, 4=lentigo maligna melanoma, 5=desmoplastic) 
• lastfup – date of last follow-up or death 
• death – censoring variable for last follow-up = status at last follow-up (0=alive; 
1=death) 
• datedisfree – date of recurrence or last follow-up 
• disfree – censoring variable for disease-free survival = status at datedisfree 
(0=censored; 1=recurrence or death) 
Statistical methods 
Descriptive statistics were obtained for each variable and tabulated.  The number of 
missing values of each variable was calculated. Median follow-up time was calculated using 
the actual follow-up periods of each patient, this being the difference in months between 
the date of sentinel node biopsy and the date of last follow-up.  The distribution of each 
variable was then examined and noted by checking its histogram.  Any outliers identified at 
this point were clarified with the research team.   
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After data cleaning, imported dates were converted into date format.  The time-to-
event variables were converted to months from SNB.  Overall survival was plotted against 
months from SNB using a Kaplan-Meier curve with Greenwood 95% confidence interval 
bands.  Descriptive statistics of the overall survival experience were also produced. 
Univariate survival analysis of each covariate was performed.  Continuous variables 
were first converted into categorical variables by dividing each into 3 groups of roughly 
equal size. A log-rank test was then used to compare the survival of groups for each 
covariate. 
Multiple imputation was performed to estimate the missing values.  The user-supplied 
Stata program by Royston (command ice) was used.7  This Stata routine performs 
imputation by a series of univariable regression models for the conditional distribution of 
the missing values.8  The complete dataset was used for the imputation including all 
patients who had no follow-up data as well as all variables collected for this study.  This was 
so that as much data as possible could be accounted for during the imputation process.  
Missing values of the time-to-event variable and the censoring variable were included.  The 
time-to-event variables were transformed logarithmically.  Count data were also 
transformed logarithmically as the regression routine of ice performs best with normally 
distributed data.  A total of 5 imputed datasets were generated.  Missing data were 
generated by the use of linear regression for continuous data, multilevel logistic regression 
for categorical data, and ordinal logistic regression for ordered categorical data.  The details 
of the settings for the imputation command are shown in Table 1.   
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Table 1 – Multiple imputation parameters using “ice”.*   
 
Variable Type Imputation strategy 
Sex (codemf) Binary categorical No missing data 
Age Continuous Linear regression 
LN area Categorical Multilevel logistic regression 
Left/right Binary categorical Logistic regression 
Log(LSG) Continuous Linear regression 
Log(SLN) Continuous Linear regression 
Log(mitosis) Continuous Linear regression 
Number of LN positive Count/ordered categorical Ordinal logistic regression 
Clark level Ordered categorical Ordinal logistic regression 
Presence of ulceration Binary categorical Logistic regression 
Breslow thickness Continuous Linear regression 
Type Categorical Multilevel logistic regression 
Log(months to last 
follow-up/recurrence) Continuous Linear regression 
Log(months to last 
follow-up/death) Continuous Linear regression 
Overall survival 
censoring variable Binary categorical Logistic regression 
Disease-free survival 
censoring variable Binary categorical Logistic regression 
*Stata command: 
. ice codemf Age  lnarea lr  logLSG logSLN logmit LNpos clarklev ulcer Breslow 
type  logmtodis logmto fup death disfree using "D:\MBiostat\2009 - 
WPP\Clean\data10.dta", cmd(logLSG logSLN logmit:regress LNpos clarklev: ologit, 
type: mlogit) m(5) 
 
The 5 imputed datasets were then analysed together with the command micombine,  
which computes an average coefficient and standard errors according to the equations 
suggested by Rubin.9   
The data were then used to build a Cox proportional hazards model using the 
“purposeful selection of covariates” method to select the variables.8  All covariates with 
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P<0.25 on univariate analysis were selected for the initial multivariate model, along with 
those covariates considered important in answering our research question.  The least 
significant terms were progressively removed from this model.  Variables were retained in 
the final multivariate model if P<0.05 or they were confounding the effect of other 
variables on the outcome.   
First degree interactions were added to the final reduced model to investigate the 
presence of effect modification. 
The final model was then assessed for: 
• presence of appropriate form for continuous variables, by assessing the 
linearity of the Martingale residuals of a model excluding the covariate of 
interest; 
• validity of the assumption of proportional hazards using Shoenfeld residuals; 
• Goodness-of-fit using Cox-Snell residuals. 
Note that Stata does not allow the performance of model diagnostics across all five 
imputed datasets, so the above were only performed on the first imputed dataset.  Due to 
this, it is expected that the residuals calculated would be higher than expected, as the final 
model is based upon the combined estimate from the models of each imputed dataset 
rather than on the particular dataset used for residual analysis. 
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Results 
Description of subjects 
3127 patients were initially identified in the database.  Of these, 14 patients were 
identified on final pathology to have either a blue naevus or melanoma in-situ.  These 
ineligible patients were excluded, leaving 3113 patients for analysis.  The median follow-up 
time for these subjects was 46.5 months. 
Data cleaning resulted in the following adjustments: 
• 12 corrected ages 
• 1 patient with Clark level “6” (does not exist) was changed to level “5” 
• 1 patient where the recurrence date was later than the last follow-up date – 
the last follow-up date was therefore adjusted to be equal to the date of 
recurrence. 
• 17 tumour types were incorrectly typed in (eg, entered in the datsheet as SM 
rather than SSM for superficial spreading melanoma). 
Patient characteristics are summarised in Table 2.  Of note is that there is a 
predominance of males.  Most common lymph node basin is in the axilla and the upper 
limb nodal basins.  The median number of nodes detected at LSG and removed at sentinel 
node surgery was the same (2 (IQR 1-3)) but the actual range was much greater for the 
latter (1-9 vs 1-31).  The consequent lymph node yield at surgery varied from 0.25 to 15.  
The Clark levels and Breslow thicknesses found in the specimen reflect a predominance 
of intermediate thickness melanoma in our patient population which is the group in which 
sentinel node surgery is most beneficial.
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Table 2 – Summary of patient characteristics and the number of missing data for each 
variable. 
 Number of 
observations 
Number 
missing (%) 
 
 
Demographic characteristics 
Male/female 3113 0 (0%) Female  1224   
Male  1889  
 
Age 3111 2 (0%) Mean 56.3 (SD 15.8) 
 
Follow-up 2953 160 (5.1%) Median 46.5 (IQR 24.1-71.2) 
 
Lymph node characteristics 
LN areas 2965 148 (4.8%) Axilla/upper limb  1365 
Groin/lower limb  886 
Neck/axial  492  
Multiple  202 
  
Left/right 2963 150 (4.8%) Left  1359   
Right  1368   
Bilateral  236  
 
Number of nodes on 
LSG 
2961 152 (4.9%) Median 2 (IQR 1-3) nodes 
Number of nodes at 
surgery 
3110 3 (0%) Median 2 (IQR 1-3) nodes 
LN positive for cancer 3110 3 (0%) 0 (0-0) nodes 
    
Characteristics of primary cancer 
Mitoses/mm2 3069 44 (1.4%) Median 3 (IQR 1-6) 
 
Clark level 3027 86 (2.8%) level 1 4   
level 2 97   
level 3 776   
level 4 1912   
level 5 238   
 
Presence of ulceration 3070 43 (1.4%) non-ulcerated  2337  
ulcerated  733  
 
Breslow thickness (mm) 3075 38 (1.2%) Mean 2.43 (SD 1.85) 
 
Tumour type 2540 573 
(18.4%) 
SSM  1048 
NM  1145 
AL  56 
LMM  48 
Desmoplastic  243  
Abbreviations: AL = Acral lentiginous melanoma; IQR = interquartile range; LMM = Lentigo maligna 
melanoma; LN = Lymph node; LSG = Lymphoscintigraphy; NM = nodular melanoma; SSM = Superficial 
spreading melanoma 
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Overall survival and disease-free survival 
The overall survival experience (with 95% Greenwood confidence bands) of the entire 
patient cohort is shown in Figure 1.  The total number of subjects with follow-up data was 
2953 (of 3113, 94.8%).  There were 542 deaths with a total time at risk of 154 770 months.  
The median duration of follow-up was 46.5 months with an interquartile range (IQR) of 24.1 
– 71.2 months.  The overall median survival time could not be estimated, but the overall 
75% survival time was 74 months. 
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Figure 1 – Kaplan-Meier survival curve for overall survival 
Disease-free survival for the entire cohort was also estimated with a Kaplan-Meier 
survival curve (Figure 2).  The 75% disease-free survival time was 44 months.   
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Figure 2 – Kaplan-Meier survival curve for disease-free survival 
The results of univariate analysis and the cut-points used for categorisation are shown 
in the following table (Table 3).   Note that the left square bracket means that the value is 
included and right round bracket means it is not included in range. 
In addition to the known factors associated with poor outcome (male sex, old age, 
presence of ulceration, thickness of tumour, positive lymph nodes), the number of nodes 
found at initial lymphoscintigraphy and the subsequent yield of lymph nodes at surgery 
were also found to be predictive factors of survival on univariate analysis.  The same factors 
that significantly affected overall survival also affected disease-free survival significantly.
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Table 3 – Summary of univariate analysis for overall survival 
 
Variable n (with follow-up) 75% survival time 
(months) 
P-value 
Sex 
 Female 
 Male 
 
 1176 
 1777 
 
 104 
 64 
<0.0001 
 
Age (years) 
 [3.4, 50.5) 
 [50.5, 64.9) 
      [64.9- 94.2] 
 
 
 968 
 988 
 995 
 
 
 138 
 88 
 49 
 
<0.0001 
 
LN areas 
 Axilla/UL 
 Groin/LL 
 Neck/axial 
 Multiple 
 
 
 1299 
 843 
 476 
 192 
 
 
 87 
 73 
 54 
 66 
 
0.0005 
 
Side of LN basin 
 Left 
 Right 
 Bilateral 
 
 
 1291 
 1289 
 228 
 
 
 79 
 71 
 77 
 
0.35 
 
Nodes at LSG (n) 
 [0, 2) 
 [2, 3) 
 [3, 9] 
 
 
 
 812 
 989 
 1005 
 
 
 103 
 70 
 66 
 
0.010 
LN at surgery (n) 
 [0, 2) 
 [2, 3) 
 [3, 31] 
 
 946 
 973 
 1031 
 
 79 
 63 
 80 
0.22 
 
Ratio of LN at surgery LSG 
  
0.011 
 <1 
 ≥1 
 602 
 2202 
 62 
 79 
 
 
 
Positive nodes (n) 
 0 
 ≥1 
 
 
 2476 
 474 
 
 
 97 
 36 
 
<0.0001 
 
Mitosis (n) 
 [0, 2) 
 [2, 5) 
 [5, 67] 
 
 
 906 
 938 
 1073 
 
 
 112 
 88 
 52 
 
<0.0001 
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Clark level 
 1 
 2 
 3 
 4 
 5 
 
 
 4 
 91 
 738 
 1811 
 231 
 
 
 - 
 131 
 103 
 69 
 45 
 
<0.0001 
 
Ulceration 
 Absence 
 Presence 
 
 
 2210 
 707 
 
 
 98 
 44 
 
<0.0001 
 
Thickness (mm) 
 [0, 1.4) 
 [1.4, 2.5) 
 [2.5, 16) 
 
 
 902 
 1030 
 989 
 
 
 145 
 97 
 43 
 
<0.0001 
 
Tumour type 
 SSM 
 NM 
 AL 
 LMM 
 Desmoplastic 
 
 
 984 
 1095 
 54 
 46 
 237 
 
 
 109 
 58 
 42 
 72 
 88 
 
<0.0001 
Abbreviations: AL = Acral lentiginous melanoma; LMM = Lentigo maligna melanoma; LN = Lymph 
node; LSG = Lymphoscintigraphy; NM = nodular melanoma; SSM = Superficial spreading melanoma 
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Table 4 – Summary of univariate analysis for disease-free survival 
 
Variable n 75% disease free 
period (months) 
Median disease 
free period 
(months) 
P-value 
Sex 
 Female 
 Male 
 
 1176 
 1778 
 
 54 
 39 
  
 162 
 140 
0.0001 
 
Age (years) 
 [3.4, 50.5) 
 [50.5, 64.9) 
      [64.9- 94.2] 
 
 
 968 
 988 
 996 
 
  
 77 
 52 
 30 
 
  
 - 
 - 
 73 
 
<0.0001 
 
LN areas 
 Axilla/UL 
 Groin/LL 
 Neck/axial 
 Multiple 
 
 
 1300 
 843 
 476 
 192 
 
  
 60 
 41 
 30 
 44 
 
  
 - 
 159 
 101 
 - 
 
<0.0001 
 
Side of LN basin 
 Left 
 Right 
 Bilateral 
 
 
 1292 
 1289 
 228 
 
  
 50 
 41 
 59 
 
  
 - 
 159 
 - 
 
0.13 
 
Nodes at LSG (n) 
 [0, 2) 
 [2, 3) 
 [3, 9] 
 
 
 812 
 989 
 1006 
 
  
 57 
 43 
 41 
 
  
 - 
 149 
 162 
 
0.012 
 
LN at surgery (n) 
 [0, 2) 
 [2, 3) 
 [3, 31] 
 
 
 946 
 973 
 1032 
 
  
 43 
 47 
 42 
 
  
 159 
 - 
 162 
 
0.91 
 
Ratio of LN at surgery/LSG 
   
0.0052 
 <1 
 ≥1 
 602 
 2203 
 38 
 48 
 149 
 162 
 
 
 
Positive nodes (n) 
 0 
 ≥1 
  
 
 2477 
 474 
 
  
 60 
 13 
 
  
 162 
 44 
 
<0.0001 
 
Mitosis (n) 
 [0, 2) 
 [2, 5) 
 [5, 67] 
 
 
 906 
 938 
 1074 
 
  
 76 
 50 
 30 
 
  
 162 
 159 
 102 
 
<0.0001 
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Clark level 
 1 
 2 
 3 
 4 
 5 
 
 
 4 
 91 
 739 
 1811 
 231 
  
 
 - 
 52 
 65 
 42 
 19 
 
  
 - 
 131 
 - 
 159 
 71 
 
<0.0001 
 
Ulceration 
 Absence 
 Presence 
 
  
 2210 
 708 
 
  
 58  
 20 
 
  
 167 
 70.9 
 
<0.0001 
 
Thickness (mm) 
 [0, 1.4) 
 [1.4, 2.5) 
 [2.5, 16) 
 
  
 902 
 1030 
 990 
 
  
 126 
 51 
 23 
 
 
 - 
 162 
 70.9 
 
<0.0001 
 
Tumour type 
 SSM 
 NM 
 AL 
 LMM 
 Desmoplastic 
 
  
 984 
 1096 
 54 
 46 
 237 
 
  
 73 
 33 
 13 
 40 
 51 
 
 
 - 
 105 
 47 
 131 
 - 
 
<0.0001 
Abbreviations: AL = Acral lentiginous melanoma; LMM = Lentigo maligna melanoma; LN = Lymph node; 
LSG = Lymphoscintigraphy; NM = nodular melanoma; SSM = Superficial spreading melanoma 
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Multivariate modelling of overall survival 
After performing multiple imputation, a multivariate proportional hazards model was 
fitted.  The initial model for overall survival included the following covariates: sex, age, 
lymph node basin, nodes found at lymphoscintigraphy, nodes extracted at surgery, whether 
lymph node yield was 100% or greater (primary outcome of interest), number of positive 
nodes, number of mitosis, presence of ulceration and tumour thickness.  Using the criterion 
of P<0.25 on univariate analysis, all but “side of LN basin” were eligible to be included.  
However, the following covariates were not included in the initial multivariate model: 
• logSLN as this is a figure which is unknown at time of surgery.  Also, by knowing 
LSG and the ratio, logSLN can be defined.  Therefore there is duplication of 
information if it is included. 
• Clark levels and tumour types were not included in the initial model despite 
having a significant effect on outcome on univariate analysis because it is well 
known clinically that these factors affect patient outcome through the 
influence of tumour thickness.   These two covariates if included will complicate 
the modelling as each of them is a multilevel categorical variable, with Clark 
levels being ordered.  In addition, both have at least 2 categories with very few 
patients.   
The initial model is shown in Table 5. 
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Table 5 – Initial model for overall survival 
 
 HR [95% Conf. Interval] z P>|z| 
Sex 
 
1.33 1.10 1.60 2.91 0.004 
Age 
 
1.03 1.02 1.04 8.55 <0.001 
LN location     0.025* 
 Lower limb vs upper 
 limb  
1.29 1.03 1.61 2.22 0.027 
 Axial vs upper limb 
 
1.42 1.11 1.80 2.85 0.004 
 Multiple vs upper limb 
 
1.19 0.84 1.70 0.97 0.33 
Log(LN detected at LSG) 
 
0.84 0.69 1.03 -1.69 0.091 
Ratio of LN at SNB vs 
LSG (≥1 vs <1)  
0.80 0.64 0.99 -2.07 0.038 
Number of LN positive 
 
1.89 1.69 2.12 11.14 <0.001 
Log(mitotic count) 
 
1.21 1.07 1.37 3.00 0.003 
Presence of ulceration 
 
1.43 1.19 1.72 3.78 <0.001 
Breslow thickness 
 
1.13 1.09 1.18 6.33 <0.001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = Sentinel LN 
biopsy. *overall P-value estimated by Wald test 
 
As can be seen from the above initial multivariate model, one of the LN location 
categories had the highest P-value.  However, using the Wald test, the overall P-value for 
LN location was 0.025 and a likelihood ratio (LR) test gave LR χ² = 10.2 with 3 degrees of 
freedom (df) and P = 0.017.  This suggests that this covariate is an important factor in 
predicting outcome, so LN location was not deleted from the model.   
 With the exception of log(LN detected at LSG), all covariates had a significant Wald 
test (P<0.05).  Log(LN detected at LSG) was significant at the 10 percent level and seemed 
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to be a relatively important clinical variable, so we checked its importance by refitting a 
model without it.  The resulting model is shown in table 6. 
 Table 6 – Comparison of models with and without log(LN detected at LSG) 
 
 Coeff P>|z| Coeff P>|z| 
Sex 
 
0.28 0.004 0.27 0.005 
Age 
 
0.03 <0.001 0.03 <0.001 
LN location  0.025*  0.065* 
 Lower limb vs upper 
 limb  
0.25 0.027 0.20 0.071 
 Axial vs upper limb 
 
0.35 0.004 0.31 0.011 
 Multiple vs upper limb 
 
0.18 0.33 0.10 0.59 
Log(LN detected at LSG) 
 
-0.17 0.091 - - 
Ratio of LN at SNB vs 
LSG (≥1 vs <1)  
-0.23 0.038 -0.15 0.14 
Number of LN positive 
 
0.64 <0.001 0.62 <0.001 
Log(mitotic count) 
 
0.19 0.003 0.19 0.002 
Presence of ulceration 
 
0.36 <0.001 0.36 <0.001 
Breslow thickness 
 
0.12 <0.001 0.12 <0.001 
Abbreviations: Coeff = log(HR); HR = Hazard ratio; LN = Lymph node; LSG = 
Lymphoscintigraphy; SNB = Sentinel LN biopsy. *overall P-value estimated by Wald test 
 
The coefficients for most variables above demonstrate minimal change, but the 
coefficients for variables describing LN location and the coefficient for LN ratio have 
changed markedly (>20%).  This suggests that log(LN detected at LSG) is an important 
confounding factor.  The LR test (LR χ² = 3.08; 1 df) gave P = 0.079.  The above therefore 
suggests that log(LN detected at LSG) is an important covariate which should not be 
removed from the final model.  
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At this point, no further variable can be deleted.   First-order interactions between LN 
ratio and other covariates were found not to be significant.  Therefore the above formed 
the final model. 
Model diagnostics (for overall survival model) 
The functional form of the continuous covariates was checked by plotting the 
Martingale residuals against the covariate of interest after fitting the Cox model without 
that covariate. 
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Figure 3 – Lowess-smoothed curves for Martingale residuals for models excluding the following 
variables plotted against the variable itself: (a) Age; (b) log(LN detected at LSG); (c) number of 
positive LN; (d) log(mitotic count); (e) Breslow thickness. 
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The plots for the continuous variables, age, log(LN detected at LSG), number of positive 
LN, log(mitotic count) and Breslow thickness all demonstrated a close to linear Lowess 
smoothed curve for the Martingale residuals (figure 3).  This suggests that the covariates 
are in an appropriate form and do not require transformation. 
Validity of the proportional hazards assumption was tested using scaled Schoenfeld 
residuals.  The results are shown in table 7.   
Table 7 – Test of proportional hazards assumption using scaled Schoenfeld 
residuals. 
 rho             chi2        df        Prob>chi2 
 
Sex 
 
0.020 
 
0.22 
 
1 
 
0.64 
 
Age 
 
0.008 0.04 1 0.84 
LN location     
 Lower limb vs upper  limb  0.090 4.73 1 0.03 
 Axial vs upper limb -0.039 0.83 1 0.36 
 Multiple vs upper limb 0.024 0.34 1 0.56 
 
Log(LN detected at LSG) 
 
0.024 
 
0.31 
 
1 
 
0.58 
 
Ratio of LN at SNB vs LSG (≥1 
vs <1)  
0.027 0.41 1 0.52 
 
Number of LN positive 
 
-0.173 15.6 1 0.0001 
 
Log(mitotic count) 
 
-0.021 0.27 1 0.61 
 
Presence of ulceration 
 
-0.054 1.66 1 0.20 
 
Breslow thickness 
 
-0.011 0.07 1 0.79 
Global test  29.2 11 0.002 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = Sentinel LN 
biopsy.  
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The above demonstrates that the proportional hazards assumption of the model has 
been violated.  This appears to be mainly due to “number of positive LN” (P=0.0001) but 
also to the indicator variable for lower limb vs upper limb LN location (P =0.03). 
The model was therefore refitted after stratifying for location of lymph nodes and the 
number of positive LN.  Note however that the distribution of the number of positive lymph 
nodes, shown in figure 4, suggests that while it is in theory a continuous variable, in fact the 
vast majority of patients had a value of 0 and very few had values greater than 1.   
0
50
00
1.
0e
+0
4
1.
5e
+0
4
Fr
eq
ue
nc
y
0 1 2 3 4 5
No of positive LN (5 imputation sets)
 
Figure 4 – Histogram demonstrating the distribution of the number of positive lymph nodes found in 
patients in the study (note that this is a histogram of 5 imputation datasets, therefore, the total 
number of observations is 15565). 
Therefore, I decided to convert this into an indicator variable with 1 indicating the 
presence of positive lymph nodes and use this binary categorical variable to stratify the 
data.  However, before stratifying the data, the new binary variable was used to refit the 
model and it was confirmed that this new model still violates the proportional hazards 
assumption. 
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 After stratifying for lymph node location and the presence of positive lymph nodes at 
SLNB, the resulting model is shown in table 8. 
Table 8 – Stratified final model for overall survival 
 HR [95% Conf. Interval] z P>|z| 
Sex 
 
1.35 1.11 1.63 3.08 0.002 
Age 
 
1.03 1.02 1.03 8.02 <0.001 
Ratio of LN at SNB vs 
LSG (≥1 vs <1)  
0.88 0.72 1.08 1.25 0.21 
Log(mitotic count) 
 
1.21 1.07 1.37 3.06 0.002 
Presence of ulceration 
 
1.42 1.18 1.71 3.76 <0.001 
Breslow thickness 
 
1.13 1.08 1.17 6 <0.001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; SNB = Sentinel LN biopsy.  
 
The baseline survival curves for the 8 strata are shown in figure 5.  As can be seen, LN 
positive and LN negative curves are quite different from each other.  Also, in the LN positive 
group, different lymph node location groups have different survival curves as well.  This is 
reassuring as it justifies our decision to stratify the data. 
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Figure 5 – “Baseline” survival curves for the 8 strata in the final model. 
The proportional hazards assumption was tested again using scaled Schoenfeld 
residuals.  This stratified model no longer violates this assumption.   
Table 9 – Test of proportional hazards assumption of stratified model using 
scaled Schoenfeld residuals. 
 rho chi2 df Prob>chi2 
Sex 
 
0.013 0.09 1 0.76 
Age 
 
0.030 0.57 1 0.45 
Ratio of LN at SNB vs LSG (≥1 
vs <1)  
-0.012 0.08 1 0.78 
Log(mitotic count) 
 
-0.024 0.34 1 0.56 
Presence of ulceration 
 
-0.047 1.22 1 0.27 
Breslow thickness 
 
-0.015 0.11 1 0.74 
Global test  2.94 6 0.82 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = Sentinel LN 
biopsy.  
 
Overall goodness of fit of the model with Cox-Snell residuals gives the following plot. 
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Figure 6 – Cumulative hazard function with Cox-Snell residuals as failure times to test goodness-of-fit 
of the model. 
This indicates that for the vast majority of observations, the goodness of fit of the 
model is high.  Only 4 observations out of 3113 appear not to be fit by the model quite so 
well. 
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Multivariate modelling of disease-free survival 
The covariates of the initial model (Table 10) were the same as for the initial overall 
survival model.   
Table 10 – Initial model for disease-free survival 
 HR [95% Conf. Interval] z P>|z| 
Sex 
 
1.20 1.03 1.40 2.33 0.02 
Age 
 
1.02 1.02 1.03 9.26 <0.001 
LN location     0.0038* 
 Lower limb vs upper 
 limb  
1.29 1.08 1.53 2.83 0.005 
 Axial vs upper limb 
 
1.33 1.10 1.60 2.93 0.003 
 Multiple vs upper limb 
 
1.04 0.78 1.39 0.28 0.779 
Log(LN detected at LSG) 
 
0.94 0.80 1.09 -0.84 0.402 
Ratio of LN at SNB vs 
LSG (≥1 vs <1)  
0.84 0.71 1.00 -1.94 0.053 
Number of LN positive 
 
1.79 1.62 1.97 11.5 <0.001 
Log(mitotic count) 
 
1.18 1.08 1.29 3.7 <0.001 
Presence of ulceration 
 
1.34 1.15 1.55 3.79 <0.001 
Breslow thickness 
 
1.12 1.09 1.16 7.06 <0.001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = Sentinel LN 
biopsy. *overall P-value estimated by Wald test 
 
The model was reduced by in turn removing the log(LN detected at LSG), as shown in 
table 11. 
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Table 11 – Reduced model for disease-free survival 
 HR [95% Conf. Interval] Z P>|z| 
Sex 
 
1.20 1.03 1.40 2.29 0.022 
Age 
 
1.02 1.02 1.03 9.24 <0.001 
LN location     0.0053* 
Lower limb vs upper 
 limb 
1.26 1.07 1.49 2.7 0.007 
Axial vs upper limb 
 
1.30 1.08 1.57 2.82 0.005 
Multiple vs upper limb 
 
1.01 0.76 1.34 0.07 0.94 
Ratio of LN at SNB vs 
LSG (≥1 vs <1) 
0.87 0.74 1.02 -1.75 0.081 
Number of LN positive 
 
1.77 1.61 1.95 11.55 <0.001 
Log(mitotic count) 
 
1.19 1.08 1.30 3.75 <0.001 
Presence of ulceration 
 
1.34 1.15 1.56 3.8 <0.001 
Breslow thickness 
 
1.12 1.09 1.16 7.01 <0.001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = Sentinel LN 
biopsy. *overall P-value estimated by Wald test 
 
In this model, the largest P-value is 0.081 for LN ratio.  As this is the variable of interest 
of the study it was kept in the model.  No further reduction in this model is possible.  First-
order interactions of LN ratio with other covariates were not significant, so this model 
forms the final model. 
Model diagnostics for the disease-free survival model 
The functional form of the continuous covariates was checked in the same way as for 
the overall survival model.  The plots for age, number of positive LN, log(mitotic count) and 
Breslow thickness all demonstrated a close to linear Lowess smoothed curve suggesting 
that the covariates are in an appropriate form and do not require transformation (figure 7). 
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Figure 7 – Lowess-smoothed curves for Martingale residuals for models excluding the following 
variables plotted against the variable itself: (a) Age; (b) number of positive LN; (c) log(mitotic count); 
(d) Breslow thickness. 
Using Schoenfeld residuals, the proportional hazards assumption was tested (Table 12).  
Age, presence of ulceration, and number of lymph nodes positive were found to have 
violated this assumption.    
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Table 12 – Test of proportional hazards assumption with Schoenfeld 
residuals. 
 rho chi2 df Prob>chi2 
Sex 
 
0.012 0.1 1 0.720 
Age 
 
0.068 4.9 1 0.026 
LN location     
Lower limb vs upper 
 limb 
0.018 0.3 1 0.594 
Axial vs upper limb 
 
-0.060 3.2 1 0.074 
Multiple vs upper limb 
 
-0.042 1.6 1 0.21 
Ratio of LN at SNB vs 
LSG (≥1 vs <1) 
0.016 0.2 1 0.63 
Number of LN positive 
 
-0.149 18.0 1 <0.0001 
Log(mitotic count) 
 
-0.030 0.9 1 0.348 
Presence of ulceration 
 
-0.104 9.6 1 0.002 
Breslow thickness 
 
-0.009 0.1 1 0.797 
Global test   49.28 10 <0.0001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = 
Sentinel LN biopsy. *overall P-value estimated by Wald test 
 
The model was therefore stratified according to the above variables.  The number of 
lymph node positive was categorised as for the analysis of overall survival.  Age was also 
categorised into the 3 categories used in univariate analysis (table 3).  This new model with 
12 strata is shown in table 13.   
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Table 13 – Stratified model for disease-free survival 
 HR [95% Conf. Interval] Z P>|z| 
Sex 
 
1.22 1.05 1.43 2.53 0.011 
LN location     0.0076* 
 Lower limb vs upper 
 limb 
1.24 1.05 1.47 2.53 0.011 
 Axial vs upper limb 
 
1.32 1.09 1.58 2.9 0.004 
 Multiple vs upper 
 limb 
1.04 0.78 1.38 0.25 0.805 
Ratio of LN at SNB vs 
LSG (≥1 vs <1) 
0.90 0.76 1.05 -1.38 0.17 
Log(mitotic count) 
 
1.18 1.08 1.30 3.71 <0.001 
Breslow thickness 
 
1.12 1.08 1.16 6.83 <0.001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = Sentinel LN 
biopsy. *overall P-value estimated by Wald test 
 
Rechecking the proportional hazards assumption gives table 14.  This demonstrates 
that whilst two LN location dummy variables were almost significant for violation of the 
proportional hazards assumption, neither was.  The global test also was non-significant 
(P=0.24).  We also investigated the possibility of refitting the model with LN location 
stratified, but found that the coefficients and P-values of the remaining variables were 
minimally changed but the model had 3 times the number of strata of the existing model 
(ie, 36 strata).  Therefore, by the principle of parsimony, we decided not to further stratify 
the model. 
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Table 14 – Proportional hazards assumption tested for the final stratified 
model for disease-free survival 
        rho          chi2       df       Prob>chi2 
Sex 
 
0.007 0.04 1 0.84 
LN location     
 Lower limb vs upper  
  limb 
0.011 0.12 1 0.73 
 Axial vs upper limb 
 
-0.062 3.36 1 0.07 
 Multiple vs upper limb 
 
-0.063 3.56 1 0.06 
Ratio of LN at SNB vs LSG 
(≥1 vs <1) 
0.014 0.18 1 0.67 
Log(mitotic count) 
 
-0.022 0. 48         1 0.49 
Breslow thickness 
 
-0.002 0.00 1 0.96 
Global test   9.19 7 0.24 
Abbreviations: HR = Hazard ratio; LN = Lymph node; LSG = Lymphoscintigraphy; SNB = 
Sentinel LN biopsy. *overall P-value estimated by Wald test 
Overall goodness of fit of the model with Cox-Snell residuals gives the following plot. 
0
1
2
3
0 .5 1 1.5 2 2.5
Cox-Snell residual
Nelson-Aalen cumulative hazard Cox-Snell residual
 
Figure 8 - Cumulative hazard function with Cox-Snell residuals as failure times to test goodness-
of-fit of the model for disease-free survival. 
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Again, like the overall survival model, the goodness-of-fit is high for the vast majority of 
the observations (except for one out of 3113).   
Comparison with complete data only analysis 
To confirm that the process of multiple imputation has not produced unexpected 
results, analysis was repeated with patients with completed data only.  Using the same 
covariates as in the models developed above after multiple imputation, Cox proportional 
hazards models were estimated using patients with complete data only.  The results are 
summarized below (table 15 for overall survival, table 16 for disease-free survival). 
Table 15 – Comparison between models for overall survival using complete data only 
(complete) and using imputed missing data (MI)  
 
HR (MI) P>|z| HR 
(complete) 
P>|z| 
Sex 
 
1.35 0.002 1.36 0.005 
Age 
 
1.03 <0.001 1.03 <0.001 
Ratio of LN at SNB vs 
LSG (≥1 vs <1)  
0.88 0.21 0.91 0.078 
Log(mitotic count) 
 
1.21 0.002 1.22 0.001 
Presence of ulceration 
 
1.42 <0.001 1.54 <0.001 
Breslow thickness 
 
1.13 <0.001 1.14 <0.001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; MI = Multiple imputation;  SNB = Sentinel LN biopsy 
As can be seen in the above table, the hazard ratio for each variable is very similar 
between the 2 models using MI data and complete data only.  This confirms that the 
multiple imputation process has not produced estimated missing values which are wildly 
abnormal.   
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Table 16 – Comparison between models using complete data only (complete) and using 
imputed missing data (MI) for disease-free survival 
 
HR (MI) P>|z| HR 
(complete) 
P>|z| 
Sex 
 
1.22 0.011 1.16 0.09 
LN location  0.0076*  0.012* 
 Lower limb vs upper 
 limb 
1.24 0.011 1.30 0.006 
 Axial vs upper limb 
 
1.32 0.004 1.32 0.010 
 Multiple vs upper limb 
 
1.04 0.805 1.03 0.865 
Ratio of LN at SNB vs 
LSG (≥1 vs <1) 
0.90 0.168 0.96 0.433 
Log(mitotic count) 
 
1.18 <0.001 1.23 <0.001 
Breslow thickness 
 
1.12 <0.001 1.14 <0.001 
Abbreviations: HR = Hazard ratio; LN = Lymph node; MI = Multiple imputation;  SNB = Sentinel LN biopsy.  
*Overall P-value estimated by Wald test. 
 
Again, for disease-free survival, the models using the different data are similar, 
although less so than for overall survival. 
Interpretation of results for a non-statistical audience 
Hazard ratio is a way of conceptualizing the risk of “failure” – in this case, it represents 
the ratio of the risk of dying at any one time in one group of patients compared to another.  
The 95% confidence interval represents the range of hazard ratios that would be found in 
95% (ie, 19 of 20) of studies if one were to repeat the study many times.  That is, one is 95% 
confident that the true hazard ratio lies within the given range.   
Overall Survival 
The final model for overall survival with hazard ratios, P-values and confidence intervals 
is shown in table 8.  Note that this model is stratified according to the presence of positive 
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LN and the location of the sentinel LN.  That is, the following results can only be interpreted 
by comparing patients with the same combination of the above two factors. 
According to this final model, we found that: 
• Male sex is associated with a 35% higher risk of death than females.  Had we 
repeated the study 20 times, the increased risk will be found to be between 11% 
and 63% greater in men than women in 19 studies, on average. 
• There is an increasing risk with increasing age.  For 2 people with an age difference 
of 1 year, the risk is 3% higher for the older person.  This will be found to be 
between 2-3% in 95% of times. 
o The hazard ratio for a 10-year age difference can also be calculated by:  
 HR10y = exp(10b1y) = exp(0.272) = 1.31 
o Therefore, in 2 people with an age difference of 10 years, the risk of death 
in the older person is 31% greater than that of the younger person.  
Similarly, the 95% confidence interval can be worked out to be 23% to 
40%. 
• The presence of ulceration is also an important factor, those patients with 
ulceration having a 42% higher risk of death at any time.  We are 95% confident 
that this lies between 18 and 71%. 
• The thicker the tumour, the higher the risk of death.  For each 1mm increase in 
thickness, the risk of death is increased by 13%.  We are 95% confident that the 
increase in the risk of death is between 8 and 17% for each 1mm increase in depth. 
• In relation to the number of mitoses found at histology, for each logarithmic unit 
difference increase of mitoses, the risk of death increases by 21%.  That is, for each 
2.7 times increase in the number of mitoses detected on histopathology, the risk of 
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death increases by 21%. We can be 95% certain that this is between 7% and 37% 
increase in risk with increasing mitotic count. 
• Finally, in relation to the outcome of interest, the lymph node yield was not found 
to have a statistically significant effect on survival.  The P-value was 0.21, which 
means that there is a 21% chance that the observed magnitude of change could 
have occurred purely by chance alone.  This is greater than our preset upper limit 
of 5% which we consider statistically significant.  In the currently sampled patients, 
it seems that the presence of a high lymph node yield (>1) at surgery will lead to a 
12% decrease of the risk of death.  However if we repeated this study many times, 
95% of times we will get a result that ranges from improving the risk of death by 
28% to increasing the risk of death by 8% (95% CI 0.72-1.08%). 
We therefore cannot conclude that a high lymph node yield at surgery (LN at SNB/LN at 
LSG>1) is associated with improved overall survival. 
The final model for disease-free survival is detailed in table 13. This model is stratified by 
age, lymph node positive status, and presence of ulceration. 
Disease-free survival 
Therefore, this study shows that: 
• Male sex is associated with a 22% higher risk of recurrence or death compared to 
females.  Had we repeated the study 20 times, the increased risk would have been 
found to be between 5% and 43% greater in men than women in 19 times, on 
average. 
• Compared to patients who have their sentinel nodes found in the upper limb 
nodes, those who have sentinel nodes found in the lower limb will have a 24% 
higher risk of recurrence/death.  If we repeated this study many times, we would 
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find that this increase in risk lies between 5 and 47% in 95% of the times.  Sentinel 
nodes being found in the neck or torso is also associated with an increased risk of 
recurrence or death of 32%.  We are 95% confident that this increase in risk is 
between 9 and 58%. 
• The thicker the tumour, the higher the risk of recurrence or death.  For each 1mm 
increase in thickness, the risk of recurrence or death is increased by 12%.  We are 
95% confident that the increase in the risk of recurrence or death is between 8 and 
16% for each 1mm increase in depth. 
• In relation to the number of mitoses found at histology, for each logarithmic unit 
increase in mitoses, the risk of recurrence or death increases by 18%.  That is, for 
each 2.7 times increase in the number of mitoses detected on histopathology, the 
risk of recurrence or death increases by 19%. We can be 95% certain that this is 
between 8% and 30% increase in risk with increasing mitotic count. 
• Finally, in relation to the outcome of interest, the lymph node yield was not found 
to have a statistically significant effect on disease-free survival.  The P-value was 
0.17, which means that there is a 17% chance that the observed magnitude of 
change could have occurred by pure chance alone.  This is greater than our preset 
upper limit of 5% which we consider statistically significant.  However, on average, 
the presence of a high lymph node yield (>1) at surgery would lead to a 10% lower 
risk of recurrence/death.  The 95% confidence interval in this case is between 24% 
decrease and 5% increase in risk of the same.     
 We therefore cannot conclude that a high lymph node yield at surgery (LN at 
SNB/LN at LSG>1) is associated with improved disease-free survival. 
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Discussion 
Missing data 
Missing data are almost inevitable in large datasets such as this one.  Missing data can 
be classified into 3 categories10:  
• Missing completely at random (MCAR) – these missing data are thought to 
arise completely randomly in that the property of “missingness” does not 
relate to any known information in the data but rather to extraneous factors 
(such as missing patient weight variable if that is due to malfunction of the 
scales on that visit.) 
• Missing at random (MAR) – this kind of missing data is the most commonly 
assumed kind.  Whilst the missing data arise apparently randomly, any 
systematic difference between missing values and observed values can be 
explained by differences in observed data.  For instance, patients with poor 
outcomes may be less likely to return for follow-up, so these patients would 
have missing follow-up data. 
• Not missing at random (NMAR) occurs when it is known that certain data are 
missing in a non-random fashion. 
It is important to distinguish between these types of missing data as they affect the 
analysis.   
There are many different ways of dealing with missing data.  The most commonly used 
way to deal with incomplete data is either to exclude the subjects with missing data from 
the analysis or to use the indicator method.  The former method may be acceptable if the 
data is indeed MCAR, however, it is often impossible to know that this is the case.  This 
method will also generate unbiased estimates if the missing data are for: 
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• an outcome variable that is measured once in each individual 
• a predictor variable that is unrelated to the outcome. 
However, even in cases where such a method generates unbiased estimates, analysing the 
data this way will lead to a loss of precision and power.10 
Another possible method of dealing with missing data is to use an “indicator method”.  
In this method, an indicator variable is added as an extra level for each variable with 
missing data.  The problem with this is that it inevitably causes bias and it also causes a 
large number of new variables.11, 12 
The best way to deal with missing data is the use of multiple imputation.10  The 
principle of this technique is based on the fact that MAR data are related to other variables, 
so their distribution can be estimated from the other measured variables.  A new set of 
data can therefore be generated with the missing data thus estimated.  Essentially, the 
estimated population distribution of the variables with missing values is re-sampled to 
create a new sample.  As the imputed data and the actual data come from the same 
population distribution, modelling using the new completed dataset would yield non-
biased estimates.  
The variance of the estimates however, would be increased compared to modelling of 
the complete data.  This additional variance from the “resampling” (imputation) process is 
minimised by combining the estimates from models of each of the imputed datasets, which 
is why multiple is preferable to single imputation.    
 Important issues that need to be considered in using this technique include: 
• The number of imputations required: it is said that 5 imputations is usually 
adequate8, 9 
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• Selecting the variables used for analysis – as many variables should be used as 
possible, especially the outcome variable as it often carries information about 
the missing variable.13 
• Non-normally distributed variables – these should be transformed to 
approximate normality before imputation. 
Limitations of results 
Retrospective studies are often limited by the design and the data that are available for 
researchers.  This is also the case in this study.   
Limitations related to study design and data 
Being an observational study rather than a randomised controlled trial, there may be 
additional confounding factors which may not have been accounted for by the multivariate 
model.  These unknown factors may lead to bias of the result.   
One of the issues in this study is the short follow-up period after sentinel lymph node 
biopsy.  Whilst the median follow-up was 46.5 months, median survival was not able to be 
estimated when calculating the overall survival.  Median disease-free survival was just able 
to be calculated. However, the natural history of melanoma is that recurrences or even 
mortality do occur many years after the primary diagnosis.  This may lead to inaccuracies in 
estimating median survival as there are few patients with more than 10 years of data. 
Another limitation of the data arises from the accuracy of the collected data.  In many 
cases, clinical databases are maintained by one individual, but the data are input by a 
variety of clinical and non-clinical staff.  There is great variation in the accuracy of the data 
entered into the database depending on who enters the data.  This is a potential source of 
bias, especially in a multi-clinician, multi-disciplinary institution such as the Sydney 
Melanoma Unit.  If, for example, different clinicians with interests in different types of 
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melanomas (eg, metastatic or high grade) record data with different quality or 
completeness, then this will bias the data.  However, this was partly ameliorated by the 
fact that consecutive patients were examined, and careful data cleaning was in place to 
review any inconsistencies in the data. 
Another important limitation to consider is that the study setting in this case is at a 
specialist melanoma unit, which may see a different population of melanoma patients than 
that encountered in more general surgical/dermatology units.  As sentinel node biopsy is 
most beneficial in patients who have intermediate thickness melanoma, this may affect the 
external applicability of this study. 
However, one good point of the current study is that the sample size is relatively large, 
which will reduce the probability of making a type 2 error.  This is important especially 
since we have found that lymph node ratio did not affect patient outcome.  Note that this 
does not impact on the potential biasing effects of unrecognised confounders. 
As this study is retrospective one is unable to determine for certain whether all sentinel 
nodes have been removed, so we utilize the lymph node yield as a surrogate for this.  A 
ratio of more than 1 does not necessarily reflect complete sentinel lymph node excision.  
Furthermore, lymphoscintigraphy is imperfect, which may also bias the outcome.  The 
quality of lymphoscintigraphy is as important in this study as the quality of surgery. 
Limitations related to scientific methodology (lymphoscintigraphy) 
Whilst multiple imputation was used to estimate missing data, there are limitations to 
this technique.  The first is the assumption that the missing data are MAR.  If there were 
data that were NMAR, then the imputed missing values would be biased.  Also, imputing 
Limitations relating to analysis 
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values of variables with a non-normal distribution may lead to imputation of extreme or 
impossible values which again may lead to bias. 
Finally, when multiple imputation is used with modelling, it is not clear whether the 
values should be imputed before the model-building process or if it should be performed 
after.  The former may lead to bias by not incorporating into the imputation process what 
can only be known after modelling (eg, non-linear functional forms of continuous 
covariates) whilst the latter can lead to bias by restricting the model-building process to 
observations with complete data.8   
In this study, we have attempted to evaluate the effect of multiple imputation by 
comparing the resulting analysis with an analysis restricted to complete data only.  The 
results confirm that multiple imputation has not led to very abnormal results in this study.  
The discrepancies seen between the two analyses probably reflect the bias due to 
restricting analysis to observations with complete data only. 
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Conclusion 
Complete extraction of all sentinel lymph nodes identified at preoperative 
lymphoscintigraphy was not found to be associated with statistically significant 
improvements in overall or disease-free survival.   
Other well-known risk factors (male sex, older age, presence of involved nodes, 
presence of ulceration, increased Breslow thickness, high mitotic count, and location of 
tumour) were once again confirmed to affect outcome. 
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Appendix – Excel data manipulation 
Note: DATA signifies original data input by data collector/investigator. 
 
 
Data table 1 
To code sex (Column D – “Code M/F”) 
 C D 
1 M/F Code M/F 
2 DATA – eg, “M”, “F” =IF(C2="M",1,IF(C2="F",0,"error")) 
 
To calculate age: 
 E F G 
1 Date of Birth Date of SNB Age 
2 DATA – in form of date DATA – in form of date =(F2-E2)/365.25 
 
To code ulceration (Column AU – “Ulcer code”) 
 AT AU 
1 Ulceration Ulcer code 
2 DATA – “Nil” or “Yes” =IF(AT2="Nil",0,IF(AT2="Yes",1, IF(AT2="","","error"))) 
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To code side (Column J – “Left or right”) and area of lymph node basin (Column T – “Final LN Area”) 
 I J K L M N O P Q R S T 
1 Area of 
lymph 
node 
Left or 
Right 
Lnarea Groin Popliteal Axilla Epitrochlea
r 
Triangular 
space 
Neck Other Reclass Final LN 
area 
2 DATA, eg, 
Rgroin, 
Laxilla 
=IF(COUNT
A(I2)=1,IF(I
SERR(FIND(
"R",I2)=TR
UE),IF(ISER
R(FIND("L",
I2))=TRUE,"
error",IF(FI
ND("L",I2)=
1,"0","2")),
IF(FIND("R"
,I2)=1,"1","
2")),"") 
=IF(COUNT
A(I2)=1,IF(I
SERR(FIND(
"/",I2))=TR
UE,IF(ISERR
(FIND("axill
a",I2))=TRU
E,IF(ISERR(
FIND("groi
n",I2))=TRU
E,IF(ISERR(
FIND("neck
",I2))=TRUE
,"error",3),
2),1),4),"") 
=IF($K2=4,I
F(ISERR(FIN
D("groin",$
I2))=FALSE,
TRUE,FALS
E),"") 
=IF($K2=4,I
F(ISERR(FIN
D("pop",$I
2))=FALSE,
TRUE,FALS
E),"") 
=IF($K2=4,I
F(ISERR(FIN
D("axil",$I2
))=FALSE,T
RUE,FALSE)
,"") 
=IF($K2=4,I
F(ISERR(FIN
D("epit",$I
2))=FALSE,
TRUE,FALS
E),"") 
=IF($K2=4,I
F(ISERR(FIN
D("triang",
$I2))=FALS
E,TRUE,FAL
SE),"") 
=IF($K2=4,I
F(ISERR(FIN
D("neck",$I
2))=FALSE,
TRUE,FALS
E),"") 
=IF($K2=4,I
F(OR(L2,M
2,N2,O2,P2
,Q2)=TRUE,
"",1),"") 
=IF(K2=4,IF
(AND(OR(L
2,M2),NOT
(OR(N2,O2,
P2,Q2))),2,I
F(AND(OR(
N2,O2,P2),
NOT(OR(M
2,L2,Q2))),
1,IF(AND(Q
2,NOT(OR(
P2,O2,N2,
M2,L2))), 
3,4))),"") 
=IF(K2=4,S
2,K2) 
 
To extract number of positive lymph node (Column Y – “NoPos”) 
 X Y 
1 Histology NoPos 
2 DATA, in the form of: “0\2”, “1\2” etc =IF(COUNTA(X2)=1,MID(X2,1,FIND("\",X2,1)-1),"") 
 
To extract tumour type code (Column AR – “Type code”) and thickness (Column AS – “Thickness”) from original data input (Column AP) 
 AP AQ AR AS 
1 Type, Thickness Type Type code Thickness 
2 DATA, in the form of “SSM 1.3”, “NM 
2.9”, etc 
=IF(COUNTA(AP2)=1,IF(COUNT(AP2)=1,
"",MID(AP2,1,FIND(" ",AP2,1)-1)),"") 
=IF(AQ2="","",IF(AQ2="SSM",1,IF(OR(A
Q2="SSM/NM",AQ2="NM"),2,IF(AQ2="
AL",3,IF(AQ2="LM",4,IF(AQ2="Des",5,IF
(OR(AQ2="MIS",AQ2="Blue"),9,"error")
)))))) 
=IF(COUNTA(AP2)=1,IF(COUNT(AP2)=1,
AP2,MID(AP2,FIND(" ",AP2,1)+1,4)),"") 
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Table 2 – Events datasheet – working out a list of dates of distant recurrences  
 
 B C D E F G H I J K L M N O P Q R 
1 PIN … … … … Date of 
SNB 
   This shaded area is a copy of a limited area 
of the main datasheet (datasheet 1).  This is 
simply to supply a list of SNB dates for lookup 
in the main data area below 
    
2 741     2/1/2001       
3
1
2
8 
… … … … … …       
                  
3
1
3
2 
 PIN 
locoregion
al 
recurrence 
PIN 
distant 
recurrenc
e 
PIN any 
recurrenc
e 
SNB date Event date Event 
type 
Event 
descriptio
n 
Recurre
nce 
     Event 
descriptio
n 2 
Local/regi
onal 
distant 
3
1
3
3 
 =IF(AND(J3
132=1,Q31
32=1,G313
2>F3132),
B3132,"") 
=IF(AND(J
3132=1,R
3132=1,G
3132>F31
32),B313
2,"") 
=IF(AND(J
3132=1,G
3132>F31
32),B313
2,"") 
=VLOOKU
P(B3132,
$A$2:$G$
3128,7,F
ALSE) 
DATA – in 
form of 
date 
DATA – 
in form 
of event 
colde 
DATA – 
eg, 
“Treatme
nt”, 
“Recurre
nce” 
=IF(I313
2="Recu
rrence",
1,0) 
=IF(I3132=
"Date of 
birth",1,0) 
=IF(I3132
="Primar
y 
Melanom
a",1,0) 
=IF(I3132
="Treatm
ent",1,0) 
=IF(I3132
="Last 
status",1,
0) 
=SUM(J3
132:N313
2) 
DATA – 
eg, 
“Surgery: 
local” or 
“Dead 
melanom
a” 
=IF(J3132
=1,IF(OR(
NOT(ISER
R(FIND("
Regional"
,P3132)))
=TRUE,N
OT(ISERR(
FIND("Loc
al",P3132
)))=TRUE,
NOT(ISER
R(FIND("l
ocoregio
nal",P313
2)))=TRU
E,NOT(ISE
RR(FIND(
"Extracap
sular",P3
132)))=TR
UE,NOT(I
SERR(FIN
D("transit
",P3132))
)=TRUE),1
,""),"") 
=IF(J3132=1,IF
(ISERR(FIND("
Distant",P313
2))=FALSE,1,""
),"") 
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. 
... … … … …             
2
9
1
4
0 
PIN 4 6 13 7   This shaded area of the data table is the output area.  It was 
then copied to the main datasheet in Excel (Sheet 1), then to 
Stata.  This represents a table with a list of PINs, date of distant 
recurrence, and a censoring variable with 1 representing the 
occurrence of distant metastasis.  A similar table was produced 
on a separate worksheet for locoregional recurrence. 
    
2
9
1
4
1 
741 =IF(ISNA(V
LOOKUP($
B29140,$D
$3131:$Q$
29122,C$2
9139,FALS
E))=TRUE, 
"",VLOOKU
P($B29140
,$D$3131:
$Q$29122,
C$29139,F
ALSE)) 
=IF(ISNA(
VLOOKUP
($B29140
,$D$3131
:$Q$2912
2,D$2913
9,FALSE))
=TRUE, 
"",VLOOK
UP($B291
40,$D$31
31:$Q$29
122,D$29
139,FALS
E)) 
=IF(ISNA(
VLOOKUP
($B29140
,$D$3131
:$Q$2912
2,E$2913
9,FALSE))
=TRUE, 
"",VLOOK
UP($B291
40,$D$31
31:$Q$29
122,E$29
139,FALS
E)) 
=IF(ISNA(
VLOOKUP
($B29140
,$D$3131
:$Q$2912
2,F$2913
9,FALSE))
=TRUE, 
"",VLOOK
UP($B291
40,$D$31
31:$Q$29
122,F$29
139,FALS
E)) 
     
 … … … … …             
 
